Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus

Autor: Johanna Westra, Peter Heeringa, K. De Leeuw, Pieter C. Limburg, Gerda Horst, F. Maas, Fleur Schaper, Hendrika Bootsma
Přispěvatelé: Translational Immunology Groningen (TRIGR), Groningen Kidney Center (GKC), Groningen Institute for Organ Transplantation (GIOT)
Rok vydání: 2017
Předmět:
0301 basic medicine
Male
Exacerbation
autoantibodies
Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]
SLE
Arthritis
DISEASE-ACTIVITY
Severity of Illness Index
Arthritis
Rheumatoid
0302 clinical medicine
Immunology and Allergy
Lupus Erythematosus
Systemic
anti-box A
HMGB1 Protein
skin and connective tissue diseases
HMGB1
RECEPTOR 4
biology
Complement C3
Middle Aged
Sjogren's Syndrome
Rheumatoid arthritis
Antibodies
Antinuclear
CHROMOSOMAL-PROTEIN 1
Biomarker (medicine)
Female
Antibody
ARTHRITIS
anti-HMGB1
Adult
ANTI-HMGB1 ANTIBODIES
Adolescent
Immunology
Enzyme-Linked Immunosorbent Assay
CLASSIFICATION
03 medical and health sciences
CYTOKINE RELEASE
Young Adult
medicine
Humans
NEPHRITIS
Aged
030203 arthritis & rheumatology
business.industry
Autoantibody
Original Articles
medicine.disease
MICE
030104 developmental biology
Case-Control Studies
Immunoglobulin G
biology.protein
business
Biomarkers
Anti-SSA/Ro autoantibodies
Zdroj: Clinical and Experimental Immunology, 188, 3, pp. 412-419
Clinical and Experimental Immunology, 188, 412-419
Clinical and Experimental Immunology, 188(3), 412-419. Wiley
ISSN: 0009-9104
Popis: Summary Autoantibodies to nuclear structures are a hallmark of systemic lupus erythematosus (SLE), including autoantibodies to nuclear protein high mobility group box 1 (HMGB1). HMGB1 consists of three separate domains: box A, box B and an acidic tail. Recombinant box A acts as a competitive antagonist for HMGB1 and might be an interesting treatment option in SLE. However, antibodies to box A might interfere. Therefore, levels of anti-box A were examined in SLE patients in association with disease activity and clinical parameters. Serum anti-box A was measured in 86 SLE patients and 44 age- and sex-matched healthy controls (HC). Serum samples of 28 patients with primary Sjögren's syndrome and 32 patients with rheumatoid arthritis were included as disease controls. Anti-HMGB1 and anti-box B levels were also measured by enzyme-linked immunosorbent assay during quiescent disease [SLE Disease Activity Index (SLEDAI) ≤ 4, n = 47] and active disease (SLEDAI ≥ 5, n = 39). Anti-box A levels in active SLE patients were higher compared to quiescent patients, and were increased significantly compared to HC and disease controls. Anti-box A levels correlated positively with SLEDAI and anti-dsDNA levels and negatively with complement C3 levels. Increased levels of anti-box A antibodies were present in the majority of patients with nephritic (73%) and non-nephritic exacerbations (71%). Antibodies to the box A domain of HMGB1 might be an interesting new biomarker, as these had a high specificity for SLE and were associated with disease activity. Longitudinal studies should be performed to evaluate whether these antibodies perform better in predicting an exacerbation, especially non-nephritic exacerbations.
Databáze: OpenAIRE
Externí odkaz: